Quidel gets CE mark for influenza assay

Quidel ($QDEL) has received the CE mark for its first molecular diagnostic test, the Influenza A+B real-time RT-PCR assay. The CE mark allows for the launch of the open box molecular platform in advance of the forthcoming influenza season in Europe. The product is not for sale in the U.S. at this time. Quidel release

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.